AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$SERA

Inglis Tiffany Eul Davis sold $972 of SERA

Inglis Tiffany Eul Davis (Chief Medical Officer) sold 486 shares of SERA PROGNOSTICS, INC. (SERA) at $2.00 on 2026-09-10.

Original reporting
SEC EDGAR · Inglis Tiffany Eul Davis
Published Sep 11, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SERA
Neutral
high confidence
Mentioned
$SERA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERANeutralLow
01

Why it matters

The transaction is a routine sale with minimal market impact.

02

Market read

Low relevance; the disclosed sale is small and unlikely to affect trading decisions.

03

What to watch

Potential upcoming clinical trial results not disclosed.

Relevance 3/10Novelty 3/10Timing: post-market 2026-09-10

Background

Form 4 filing reports insider transactions required by SEC; provides transparency on insider holdings.

Company-level read

Ticker impact

$SERANeutralHigh confidence
Context

Chief Medical Officer sold 486 shares for $972, reducing her stake to 91,589 shares.

Expected impact

No significant impact; price likely unchanged.

Evidence & confidence

The sale size is small relative to float and total holdings, and no broader context suggests distress.

Market effects

Sector

None; insider activity does not affect biotech sector broadly.

Regional

None; limited to Sera Prognostics shareholders.

Global

None

Counterpoint

What could challenge this read

Even small insider sells can signal upcoming negative news.

Key entities

  • Officer
    Inglis Tiffany Eul Davis

    Chief Medical Officer of Sera Prognostics, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SERA insider trading history →

Related articles

AUG 19
$SERAMed

Sera (SERA) Q2 2026 Earnings Call Transcript

Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.

fool.com2 min
AUG 12
$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.

prnewswire.com6 min
AUG 12
$SERAMed

SERA PROGNOSTICS, INC. (SERA): Results of Operations and Financial Condition

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t

SEC EDGAR 8-K4 min